Innovative therapeutics

Investors

BioMarin to Present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco
Jan 5, 2016

SAN RAFAEL, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 8:30 am PT, or 11:30 am ET, in San Francisco, California. To access the live webcast, please visit the investor section of the BioMarin website, www.BMRN.com. A replay will also be archived on the site for at least one week following the event.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.

Contacts:

Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558

Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information